AOD-9604
AOD-9604. The lipolytic fragment of growth hormone, surgically separated from everything else GH does. Fat mobilization without receptor binding, IGF-1 elevation, or glucose disruption.
Clinician-prescribed. Ships from a licensed U.S. pharmacy.
The Lipolytic Domain. Nothing Else Attached.
Growth hormone mobilizes fat. It also elevates glucose, causes insulin resistance, drives IGF-1, and produces fluid retention. These effects come from different structural regions of the same molecule. AOD-9604 is the C-terminal fragment, physically separated from every receptor-binding domain responsible for systemic effects.
It upregulates beta-3 adrenergic receptors on fat cells, restoring the lipolytic sensitivity that obesity suppresses. The cAMP-PKA-HSL cascade releases stored triglycerides as free fatty acids. Simultaneously, ACC inhibition reduces new fat synthesis by ~22% and glucose incorporation into lipid by ~50%. Two directions. One compound. No GH receptor binding at any concentration tested.
The Evidence
Other Fat Loss Approaches vs. AOD-9604 (GH Fragment 176-191)
| Other Fat Loss Approaches | AOD-9604 (GH Fragment 176-191) |
|---|---|
| Exogenous HGH produces lipolysis alongside IGF-1, glucose, and insulin disruption | Lipolytic mechanism of GH without receptor binding, IGF-1, or glucose effects |
| GLP-1 agonists work through appetite suppression, not direct fat tissue signaling | Operates directly on adipose tissue, complementary to appetite-based interventions |
| Stimulant fat burners cause cardiovascular stress and rapid tolerance | No cardiovascular stimulation, no tolerance development documented |
| Oral carnitine transports fat but does not mobilize it from adipocytes | Mobilizes fatty acids from storage via beta-3 AR and HSL activation |
| Caloric restriction triggers adaptive metabolic slowdown over time | Restores lipolytic sensitivity rather than triggering adaptive resistance |
| Each approach carries systemic trade-offs or diminishing returns | Structural selectivity confirmed in 900+ participants across six trials |
Details
The mechanism operates through two pathways: lipolysis stimulation via beta-3 adrenergic receptor upregulation and HSL activation, and lipogenesis inhibition via acetyl-CoA carboxylase downregulation. Simultaneously stimulates fat breakdown while suppressing fat formation.
Six clinical trials involving 900+ participants established a safety profile comparable to placebo. No IGF-1 elevation. No glucose changes. No growth effects. The selectivity is structural, not dose-dependent.
Emerging research shows cartilage repair potential. In an osteoarthritis rabbit model, intra-articular AOD-9604 enhanced cartilage regeneration, with synergistic improvement when combined with hyaluronic acid.
Your prescribing provider will determine dosing frequency and cycle length. Store refrigerated at 36 to 46 degrees Fahrenheit. Protect from light.
Disclaimer and Transparency
Important Information About Compounded Injectables
- Compounded medications are not reviewed or approved by the FDA and do not undergo the same pre-market evaluation as FDA-approved drugs.
- IVUSE peptide injections are prepared using peptide ingredients by FDA-registered, U.S.-licensed 503A & 503B compounding pharmacies, where available and clinically appropriate.
- Availability and formulation may vary based on state regulations, evolving clinical guidance, and pharmacy partners.
All prescriptions, treatment decisions, and care plans are made independently by licensed healthcare providers using their professional judgment. Images and product depictions are for illustration only; actual packaging and supplies may vary.
*If you are interested in a prescription product, IVUSE will coordinate a telehealth visit with a licensed medical provider who will determine whether you are an appropriate candidate based on your health profile and current standards of care. If approved, a prescription will be issued and filled by one of our partner pharmacies. All prescriptions are subject to provider discretion and clinical appropriateness.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. All information provided here is for educational purposes only and does not replace personalized medical advice from a qualified healthcare professional.
Stop the medication and contact your provider if you experience persistent or concerning symptoms. Seek immediate medical care if you develop signs of a severe allergic reaction (such as hives, facial swelling, or difficulty breathing) or any rapidly worsening symptom.
What happens next
Choose Your Protocol
No consultation fee. No hidden costs. Single vials or a full 12-week cycle.
Complete Your Clinical Intake
A board-certified clinician reviews your health history, medications, and goals. Asynchronous. No appointments. No waiting rooms.
Your Prescription Ships
Compounded by a licensed U.S. pharmacy. Delivered to your door in 2-4 business days. Cold-shipped when required.
Stack Your Protocol
Semaglutide or Tirzepatide
GLP-1 medications (Semaglutide and Tirzepatide) regulate appetite and insulin sensitivity at a systemic level. Pairing with AOD-9604 adds a direct fat metabolism layer, so you're controlling intake and accelerating breakdown simultaneously.
Tesamorelin
Tesamorelin is a GHRH analog that stimulates natural growth hormone production to reduce deep visceral fat. Stacked with AOD-9604, it creates a two-compartment approach: Tesamorelin targets the hidden abdominal fat while AOD-9604 works on the subcutaneous fat you can see and feel.
LIPO+
LIPO+ is a lipotropic injection blend (methionine, inositol, choline, B vitamins) that supports the liver's ability to process and clear fat. Adding AOD-9604 means you're breaking fat down faster and actually moving it out efficiently, preventing redistribution and keeping energy levels up during active loss.
You've been doing everything right. AOD-9604 is how your body finally catches up.
AOD-9604 is a targeted peptide fragment that activates fat metabolism without affecting blood sugar, appetite, or growth hormone levels. Clinician-prescribed. Delivered to your door in 2 to 4 business days.
AOD-9604 is a prescription peptide. Your order initiates a clinical intake. A board-certified clinician reviews your health history before your prescription ships. AOD-9604 is not FDA-approved for weight loss. If you are pregnant, breastfeeding, or have a known sensitivity to HGH-derived compounds, AOD-9604 may be contraindicated. Results vary by individual.
